Anti-tumor activity of Shikonin against afatinib resistant non-small cell lung cancer via negative regulation of PI3K/Akt signaling pathway

Targeting Cell Necroptosis and Apoptosis Induced by Shikonin via Receptor Interacting Protein Kinases in Estrogen Receptor Positive Breast Cancer Cell Line, MCF-7

(2018) Zahra Shahsavari et al.   Anti-Cancer Agents in Medicinal Chemistry

LncRNA-MALAT1 contributes to the cisplatin-resistance of lung cancer by upregulating MRP1 and MDR1 via STAT3 activation

(2018) Zhixian Fang et al.   BIOMEDICINE & PHARMACOTHERAPY

Overview of the LUX-Lung clinical trial program of afatinib for non-small cell lung cancer

(2018) Namita Sharma et al.   CANCER TREATMENT REVIEWS

Shikonin enhances sensitization of gefitinib against wild-type EGFR non-small cell lung cancer via inhibition PKM2/stat3/cyclinD1 signal pathway

(2018) Jian-cai Tang et al.   LIFE SCIENCES

Lung Cancer Biopsies

(2018) Amita Sharma et al.   RADIOLOGIC CLINICS OF NORTH AMERICA

Afatinib restrains K-RAS–driven lung tumorigenesis

(2018) Herwig P. Moll et al.   Science Translational Medicine

Shikonin exerts antitumor activity in Burkitt’s lymphoma by inhibiting C-MYC and PI3K/AKT/mTOR pathway and acts synergistically with doxorubicin

(2018) Fan Ni et al.   Scientific Reports

Efficacy of Shikonin against Esophageal Cancer Cells and its possible mechanisms in vitro and in vivo

(2018) Jian-Cai Tang et al.   Journal of Cancer

Senescence Inducer Shikonin ROS-Dependently Suppressed Lung Cancer Progression

(2018) Hongming Zheng et al.   Frontiers in Pharmacology

Polyphyllin I modulates MALAT1/STAT3 signaling to induce apoptosis in gefitinib-resistant non-small cell lung cancer

(2018) Qi Yang et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

Shikonin Inhibited Migration and Invasion of Human Lung Cancer Cells via Suppression of c-Met-Mediated Epithelial-to-Mesenchymal Transition

(2017) Yei-San Hsieh et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Polyphyllin VII increases sensitivity to gefitinib by modulating the elevation of P21 in acquired gefitinib resistant non-small cell lung cancer

(2017) Honggang Wang et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

Cost-Effectiveness Analysis of Afatinib versus Gefitinib for First-Line Treatment of Advanced EGFR -Mutated Advanced Non–Small Cell Lung Cancers

(2017) Christos Chouaid et al.   Journal of Thoracic Oncology

Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation

(2017) Toshimitsu Yamaoka et al.   MOLECULAR CANCER RESEARCH

Shikonin inhibits gefitinib-resistant non-small cell lung cancer by inhibiting TrxR and activating the EGFR proteasomal degradation pathway

(2017) Xia Li et al.   PHARMACOLOGICAL RESEARCH

Shikonin induces apoptosis of lung cancer cells via activation of FOXO3a/EGR1/SIRT1 signaling antagonized by p300

(2016) Yun-Ji Jeung et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Shikonin Derivative DMAKO-05 Inhibits Akt Signal Activation and Melanoma Proliferation

(2016) Yao-yao Yang et al.   Chemical Biology & Drug Design

PAK1 Is a Novel Therapeutic Target in Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma Activated by the PI3K/AKT Signaling Regardless of EGFR Mutation

(2016) D.-W. Wu et al.   CLINICAL CANCER RESEARCH

miR-223 reverses the resistance of EGFR-TKIs through IGF1R/PI3K/Akt signaling pathway

(2016) JING HAN et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

(2016) Keunchil Park et al.   LANCET ONCOLOGY

Paris Saponins enhance radiosensitivity in a gefitinib-resistant lung adenocarcinoma cell line by inducing apoptosis and G2/M cell cycle phase arrest

(2016) PENG-JUN ZHAO et al.   Molecular Medicine Reports

The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling

(2016) Laurence Booth et al.   Oncotarget

Paris Saponin I Sensitizes Gastric Cancer Cell Lines to Cisplatin via Cell Cycle Arrest and Apoptosis

(2016) Shuichuan Song et al.   MEDICAL SCIENCE MONITOR

Anticancer Effects of Paris Saponins by Apoptosis and PI3K/AKT Pathway in Gefitinib-Resistant Non-Small Cell Lung Cancer

(2016) XinHai Zhu et al.   MEDICAL SCIENCE MONITOR

Therapeutic potential of Ginsenoside Rg3 via inhibiting Notch/HES1 pathway in lung cancer cells

(2016) Ruzhen Zheng et al.   Translational Cancer Research

γ Secretase Inhibitor BMS-708163 Reverses Resistance to EGFR Inhibitor via the PI3K/Akt Pathway in Lung Cancer

(2015) Mian Xie et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

β-hydroxyisovaleryl-shikonin induces human cervical cancer cell apoptosis via PI3K/AKT/mTOR signaling

(2015) DAN LU et al.   Oncology Letters

FGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitor

(2015) Koichi Azuma et al.   Oncotarget

Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models

(2014) Yiqing Qu et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Inhibition of cell proliferation by mild hyperthermia at 43°C with Paris Saponin I in the lung adenocarcinoma cell line PC-9

(2014) PENGJUN ZHAO et al.   Molecular Medicine Reports

Paris saponin I induces apoptosis via increasing the Bax/Bcl-2 ratio and caspase-3 expression in gefitinib-resistant non-small cell lung cancer in vitro and in vivo

(2014) HAO JIANG et al.   Molecular Medicine Reports

Effect of shikonin on multidrug resistance in HepG2: The role of SIRT1

(2014) Yong-Dong Jin et al.   PHARMACEUTICAL BIOLOGY

Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition

(2014) Simona Coco et al.   Targeted Oncology

Effect of Paris saponin I on radiosensitivity in a gefitinib-resistant lung adenocarcinoma cell line

(2014) HAO JIANG et al.   Oncology Letters

The PI3K/AKT pathway promotes gefitinib resistance in mutantKRASlung adenocarcinoma by a deacetylase-dependent mechanism

(2013) Victor Jeannot et al.   INTERNATIONAL JOURNAL OF CANCER

Impact of EGFR Inhibitor in Non–Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis

(2013) Chee Khoon Lee et al.   JNCI-Journal of the National Cancer Institute

Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinib

(2011) Vince D. Cataldo et al.   NEW ENGLAND JOURNAL OF MEDICINE